AC Immune

ACIU

Valor de mercado US$ 238 mi

SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.

AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's disease.

AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104 in early-stage Parkinson's disease. Progress in the pipeline includes Takeda-partnered ACI-24 for prodromal Alzheimer's, triggering a $12M milestone and showing antibody responses at all dose levels. Brain-penetrant NLRP3 inhibitor ACI-19764 advances, with phase 1/1b initial data at the end of 2026 and final data in the 1st half of 2027, targeting neuroinflammatory and metabolic disorders.

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson's disease (PD). The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity as the basis for a Phase 3 decision.

AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.

AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.25 per share a year ago.

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program targeting intracellular Tau progresses with Lilly Initiation of Alzheimer's disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda Cash resources of CHF 75.4 million as of June 30, 2026, provide funding into Q4 2027 Lausanne, Switzerland, August 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today provided a corporate and financial update for the half-year ended June 30, 2026. Martin Zügel, MD, interim CEO of AC Immune and Chair of the Board of Directors, commented: “AC Immune is moving towards key clinical milestones in two of our wholly-owned programs, a growing focus for AC Immune.

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference® 2026, taking place July 12-15 in London, UK. Across these AAIC presentations, we are showing how AC Immune's Morphomer®-based small molecule approach has generated differentiated therapeutic and imaging assets.

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer's disease (AD) cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3 Ongoing AD4 cohort includes additional adjuvant designed to enhance ACI-24 responses Lausanne, Switzerland, June 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients with prodromal Alzheimer's disease (AD) in the Phase 1b/2 ABATE trial following 12 months of treatment with ACI-24 anti-amyloid beta (Abeta) active immunotherapy. In the trial to date, ACI-24 has been generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema (ARIA-E).

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years Final data from Part 1 of VacSYn trial expected in H2 2026 Lausanne, Switzerland, June 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune's anti-alpha-synuclein (a-syn) active immunotherapy, in early Parkinson's disease (PD).